ANNEX  
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
The  Member  States  should  ensure  that  all  conditions  or  restrictions  with  regard  to  the  safe  and 
effective use of the medicinal product described below are implemented. 
The MAH shall provide physicians prior to launch with an educational material that will include the 
following components of information: 
• 
• 
Need and clinical importance of adverse drug reaction (ADR) reporting in general. 
Background  data  on  erythropoietin  antibody-mediated  pure  red  cell  aplasia  (AEAB-mediated 
PRCA) associated with erythropoiesis stimulating agents (ESA) treatment. 
List of diagnoses or adverse events (AE) terms that trigger ADR reporting for MIRCERA . 
A questionnaire to gather detailed ADR report documentation. 
The MAH’s offer of testing or re-testing antibody (AB) status in a reference laboratory. 
Literature to provide information on loss of effect and its differential causes, the definition of 
AEAB-mediated PRCA, the diagnostic work-up of potential AEAB-mediated PRCA, the need 
of  discontinuation  of  ESA  treatment  due  to  cross-reactivity  with  other  ESAs  on  diagnosis  of 
AEAB-mediated PRCA.. 
• 
• 
• 
• 
2
 
 
 
 
 
 
